Mark E. Strome - 03 Jan 2024 Form 4 Insider Report for Zivo Bioscience, Inc. (ZIVO)

Role
10%+ Owner
Signature
/s/ Mark E. Strome
Issuer symbol
ZIVO
Transactions as of
03 Jan 2024
Net transactions value
+$1,514,250
Form type
4
Filing time
31 Dec 2024, 06:47:29 UTC
Previous filing
18 Jul 2023
Next filing
20 Jun 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ZIVO Common Stock Purchase $1,514,250 +75,000 +23% $20.19 398,683 26 Dec 2024 By entity F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ZIVO Common Stock Purchase Warrant Purchase $0 +7,500 +20% $0.000000 44,171 26 Dec 2024 Common Stock 7,500 $20.19 By entity F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported securities are held by Strome Mezzanine Fund II, LP ("SMF II). Strome Investment Management, LP is the general partner of SMF II. Strome Group, Inc. is the general partner of Strome Investment Management, LP. Mark E. Strome is the President and CEO of Strome Group, Inc. Mr. Strome, Strome Investment Management, LP and Strome Group, Inc. (together, the "Reporting Persons") may be deemed to share voting and investment power for the shares held by SME II. The Reporting Persons disclaim beneficial ownership of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934 (the "Exchange Act"), except to the extent of their pecuniary interest therein. This filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owner of any equity securities reported herein.